Dr. Reddy's introduces Debiopharm prostate cancer medication in India
Dr. Reddy's Laboratories has launched Swiss-based Debiopharm's Pamorelin LA , indicated for locally advanced or metastatic, hormone-dependent prostate cancer, in India.
Pursuant to the deal signed between the two companies, Dr. Reddy's has exclusive commercialization rights for the product, which will be exported from Debio Recherche Pharmaceutique, in India.
The Indian company will initially make the product available to urologists and oncologists across the country.
Debiopharm Group president and founder Rolland-Yves Mauvernay said, "This major step enables us to implement our strategy in one of the most important markets in Asia. This is only the logical continuation to a harmonious working relationship shared with Dr. Reddy's over the years."
Pamorelin LA contains Triptorelin, an agonist analogue of the natural gonadotropin-releasing hormone, as the active ingredient.
CommentsPost a comment
Comments may be moderated for spam, obscenities or defamation.
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs